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I.  General information 
 
A.  Description of organism 
 
Bacillus anthracis is an aerobic, spore-forming, nonmotile, large, gram-positive rod. 
 
B.  History 
 
The first recorded description of anthrax is in the Book of Genesis, wherein the disease was 
referred to as the fifth plague (1491 BC) and was responsible for killing Egyptian cattle.  
Additional descriptions of anthrax affecting both animals and humans have been recorded 
in the early literature of Hindus, Greeks, and Romans.  A pandemic, referred to as the 
“black bane,” swept through Europe in the 17th century and was responsible for many 
animal and human deaths.  The human form of disease was later referred to as the 
“malignant pustule.” 
 
During the 19th century, several distinguished microbiologists characterized the pathologic 
basis of the disease and attempted to develop a vaccine to combat the problem of anthrax in 
the livestock industry.  The first field-tested vaccine, developed by Pasteur in 1881 as an 
attenuated spore vaccine, was followed in 1939 by Sterne’s development of a vaccine 
consisting of a spore suspension of an avirulent, nonencapsulated live strain of B. anthracis.  
The vaccine remains in use today for the vaccination of livestock. 
 
The first reports of outbreaks associated with occupational cutaneous and respiratory 
anthrax occurred in the mid-1800s in the industrialized parts of Europe, namely England 
and Germany.  Cutaneous forms of the disease resulted from handling hides, wool, and hair; 
aerosol-creating activities such as carding wool (“woolsorter’s disease”) or handling 
contaminated sacks of dried bones in the production of bonemeal were responsible for the 
respiratory form of the disease.  Early in the 20th century, in the United States, anthrax 
occurred in individuals who handled materials that had been woven from contaminated 
animal fibers.  Since that time, the number of reported cases in developed countries has 
steadily declined.  This decline can be attributed to the administration of a cell-free anthrax 
vaccine in individuals who work in a high-risk industry, a decrease in importation of 
potentially contaminated animal products, improved animal husbandry, and the emphasis 
placed on the practice of hygiene in industry.   
 
C. Geographic distribution 
 
Although anthrax can be found globally in temperate zones, it is more often a risk in 
countries with less standardized and less effective public health programs.  Areas currently 
listed as high risk are South and Central America, Southern and Eastern Europe, Asia, 
Africa, the Caribbean, and the Middle East.  Anthrax infrequently occurs in livestock and 
wildlife in North America; however, anthrax outbreaks have been reported among deer 
from Texas and among wood buffalo in the Northwest Territory in Canada.  Animal 
infections in the United States are reported most often in Texas and North and South 
Dakota.  
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D. Clinical presentation  
 
Humans can become infected with B. anthracis by handling products or consuming 
undercooked meat from infected animals.  Infection may also result from inhalation of B. 
anthracis spores from contaminated animal products, such as wool, or the intentional 
release of spores.  Human-to-human transmission has not been reported.  Three forms of 
anthrax occur in humans: cutaneous, gastrointestinal, and inhalational.  
 
1. Cutaneous anthrax:  Cutaneous infections occur when the bacterium or spore enters  
a cut or abrasion on the skin.  Skin infection begins as a raised itchy bump or papule that 
resembles an insect bite.  Within 1 to 2 days, the bump develops into a fluid-filled 
vesicle, which ruptures to form a painless ulcer (called an eschar), usually 1 to 3 cm in 
diameter, with a characteristic black necrotic (dying) area in the center. Pronounced 
edema is often associated with the lesions because of the release of edema toxin by B. 
anthracis.  Lymph glands in the adjacent area may also swell. Approximately 20% of 
untreated cases of cutaneous anthrax result in death either because the infection becomes 
systemic or because of respiratory distress caused by edema in the cervical and upper 
thoracic regions.  Deaths are rare following appropriate antibiotic therapy, with lesions 
becoming sterile within 24 h and resolving within several weeks.   
        
2. Gastrointestinal anthrax:  The gastrointestinal form of anthrax may follow the  
consumption of contaminated meat from infected animals and is characterized by an 
acute inflammation of the intestinal tract.  Initial signs of nausea, loss of appetite, 
vomiting, and fever are followed by abdominal pain, vomiting of blood, and severe 
bloody diarrhea.  The mortality rate is difficult to determine for gastrointestinal anthrax, 
but is estimated to be 25 to 60% if not treated.  
        
3. Inhalational anthrax:  Inhalational anthrax results from inhaling B. anthracis spores  
and is most likely following an intentional aerosol release of B. anthracis.  After an  
incubation period of 1 to 6 days (depending on the number of inhaled spores), disease  
onset is gradual and nonspecific.  Fever, malaise, and fatigue may be present initially,  
sometimes in association with a nonproductive cough and mild chest discomfort.   These 
initial symptoms are often followed by a short period of improvement (ranging  
from several hours to days), followed by the abrupt development of severe respiratory 
distress with dyspnea (labored breathing), diaphoresis (perspiration), stridor (high- 
pitched whistling respiration), and cyanosis (bluish skin color).  Shock and death usually 
occur within 24 to 36 h after the onset of respiratory distress, and in later stages, 
mortality approaches 100% despite aggressive treatment.  Physical findings are usually 
nonspecific.  The chest X-ray is often pathognomonic (disease -specific), revealing a 
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II.  Procedures: Bacillus anthracis 
 
   A. General: The procedures described below function to rule out or presumptively identify  
B. anthracis from clinical specimens or isolates.  
 
B. Precautions:  These procedures should be performed in microbiology laboratories that  
use Biological Safety Level-2 (BSL-2) practices.  
    
C. Specimens  
  
1. Acceptable specimens: Collect other specimens if/as clinically indicated (e.g., 
cerebrospinal fluid [CSF], lymph node biopsy).  Refer to Appendixes for information on 
nasal specimens for screening. 
 
a. Cutaneous anthrax 
(1) Vesicular stage:  Aseptically collect vesicular fluid on sterile swabs from 
previously unopened vesicles.  Note: The anthrax bacilli are most likely to be  
seen by Gram stain in the vesicular stage. 
(2) Eschar stage:  Collect eschar material by carefully lifting the eschar’s outer     
   edge; insert a sterile swab, then slowly rotate for 2-3 sec beneath the edge  
of the eschar without removing it. 
 
b. Gastrointestinal anthrax 
(1) Blood cultures:  Collect appropriate blood volume and number of sets per    
laboratory protocol.  In later stages of disease (2-8 days post-exposure) blood 
cultures may yield the organism, especially if obtained before antibiotic 
treatment.  
(2) Stool:  Transfer ≥5 g of stool directly into a clean, dry, sterile, wide-mouth, leak-
proof container. 
(3) Rectal swab:  For patients unable to pass a specimen, obtain a rectal swab by  
   carefully inserting a swab 1 inch beyond the anal sphincter. 
 
c. Inhalational anthrax 
(1) Blood cultures:  Collect appropriate blood volume and number of sets per  
   laboratory protocol.     
(2) Sputum:  Collect >1 ml of a lower respiratory specimen into a sterile container.   
Inhalational anthrax usually does not result in sputum formation. 
          
2. Rejection criteria: Use standard laboratory criteria. 
 
3. Specimen transport and storage: Refer to Shipping Procedure. 
       a.  Swabs:  Transport directly to laboratory at room temperature.  For transport  
time >1 h, transport at 2-8°C. 
b. Stool:  Transport unpreserved stool to laboratory within 1 h.  For transport time  
>1h, transport at 2-8°C.       
 c. Sputum:  Transport in sterile, screw-capped container at room temperature  
when transport time is <1 h.  For transport time >1 h, transport at 2-8°C. 
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d. Blood culture:  Transport directly to laboratory at room temperature. 
 
D. Materials 
    
1. Reagents 
       a. Gram stain reagents 
       b. Catalase reagent (3% hydrogen peroxide) 
    c. Motility media (or slide, coverslips, saline for wet mount) 
       d. Sterile saline 
       e.  India ink (an optional test, refer to Appendix) 
  
     2. Media 
       a. 5% sheep blood agar (SBA) or equivalent 
    b. Chocolate agar (CA) 
    c. MacConkey agar (MAC) 
       d. Phenyl ethyl alcohol agar (PEA) 
       e. Blood culture bottles 
    f. Tubed motility media 
    g. Tryptic soy broth (TSB), or equivalent 
    h. Thioglycolate broth or equivalent 
 
  3. Equipment/miscellaneous 
       a. Blood culture instrument (optional) 
       b. Light microscope with 10X, 40X and 100X objectives and 10X eyepiece 
   c. Microscope slides and coverslips 
   d. Disposable bacteriologic inoculating loops 
   e. Incubator, 35-37oC, ambient preferred (CO2 enriched is acceptable)   
 
E. Quality control:  Document all quality control results for the following tests per standard  
laboratory procedure/protocol.   
 
F. Stains and smears: Gram stain  
 
1. Procedure:  Perform Gram stain procedure/QC per standard laboratory protocol. 
2. Interpretation 
a. B. anthracis is a large gram-positive rod (1-1.5 X 3-5 µm). 
b.  Blood and impression smears:  Vegetative cells seen on Gram stain of blood and 
impression smears are in short chains of 2-4 cells that are encapsulated, which may be 
seen on the Gram stain as clear zones around the bacilli.  Spores are not present in 
clinical samples unless exposed to low CO2 levels, such as those found in ambient 
atmosphere; higher CO2 levels within the body inhibit sporulation.  The presence of 
large encapsulated gram-positive rods in the blood is strongly presumptive for B. 
anthracis identification.  Refer to Fig. A2. 
c. Growth on SBA or equivalent medium:  B. anthracis forms oval, central-to-subterminal 
spores (1 X 1.5 µm) on SBA that do not cause significant swelling of the cell; 
frequently occur as long chains of bacilli. However, cells from growth on SBA 
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regardless of the incubation conditions (ambient atmosphere or CO2 enriched) are not 
encapsulated. Refer to Fig. A3a and Fig. A3b.  
 
   G. Cultures 
 
 1. Inoculation and plating procedure:  Inoculate and streak the following media for  
isolation of the respective specimen types.  Note: Standard media should be used  
according to normal laboratory procedures. 
       a. Blood cultures:  Process following routine laboratory protocol.  
b. Cutaneous swab specimens:  Plate directly on media used routinely for surface  
wounds such as SBA, MAC, and broth enrichment, and prepare smears for staining.  
Note: B. anthracis does not grow on MAC. 
c. Stool:  Plate directly on appropriate media, such as PEA, SBA, and MAC. 
d. Sputum specimens:  Plate directly on media used routinely, such as SBA, MAC, and 
CA, and prepare smears for staining.       
 
2. Incubation 
   a. Temperature:  35-37°C 
       b. Atmosphere:  Ambient preferred, CO2 is acceptable. 
       c. Length of incubation:  Hold primary plates for at least 3 days; read daily.  Examine  
plates within 18-24 h of incubation.  Growth of B. anthracis may be observed as early 
as 8 h after incubation.   
  
3. Colony characteristics of B. anthracis 
       a. After incubation of SBA plates for 15-24 h at 35-37°C, well isolated colonies of B.  
anthracis are 2-5 mm in diameter.  The flat or slightly convex colonies are  
irregularly round, with edges that are slightly undulate (irregular, wavy border),  
and have a ground-glass appearance.  There may be often comma-shaped  
projections from the colony edge, producing the "Medusa-head" colony.  Refer to  
Fig. A4.  
b. B. anthracis colonies on SBA usually have a tenacious consistency.  When teased  
with a loop, the growth will stand up like beaten egg white; refer to Fig. A5.  In  
contrast to colonies  of B. cereus and B. thuringiensis, colonies of B. anthracis are  
not β-hemolytic; refer to Fig. A6.  However, weak hemolysis may be observed  
under areas of confluent growth in aging cultures and should not be confused with  
β-hemolysis. 
c. When examining primary growth media, it is important to compare the extent of  
growth on SBA plates with that on MAC.  B. anthracis grows well on SBA but does 
not grow on MAC.         
d. B. anthracis grows rapidly; heavily inoculated areas may show growth within 6-8 h  
and individual colonies may be detected within 12-15 h.  This trait can be used to  
isolate B. anthracis from mixed cultures containing slower-growing organisms. 
 
H. Motility test:  Wet mount or motility medium 
 
  1. Purpose:  Used to determine motility of suspected isolates.  B. anthracis is nonmotile.   
Two methods are given, the wet mount and the motility medium test.       
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2. Wet mount procedure 
a. Deliver 2 drops (approximately 0.1 ml) of TSB, or equivalent, into a sterile glass tube.  
Using an inoculating loop, transfer a portion of the suspect colony from a 12-20 h 
culture and suspend the growth in the broth medium. 
   b. Alternatively, a loopful of medium from a fresh broth culture can be used.     
c. Transfer 10 µl of the suspension to a microscope slide and overlay with a coverslip. 
  d. Examine slide under a microscope using the 40X objective (total magnification  
400X; may also be viewed at 1000X with oil objective).   
        e. Discard slide(s) following standard laboratory procedures, such as into 0.5%   
   hypochlorite solution. 
  
3. Motility medium test procedure 
       a. Using a sterile inoculating needle, remove a portion of growth from an isolated,  
suspect colony after 18-24 h incubation. 
b. Inoculate the motility medium by carefully stabbing the needle 3-4 cm into the  
medium and then drawing the needle directly back out so that a single line of  
inoculum can be observed. 
  c. Incubate the tube at 35-37°C in ambient atmosphere for 18-24 h.    
 
4. Interpretation of motility results:  Lack of motility is unusual among Bacillus spp.  
and is therefore useful in the preliminary identification of B. anthracis isolates. 
       a. Wet mount 
         (1) Positive result:  Motile organisms will be observed moving throughout the  
suspension. Observe that the movement may be sluggish/slower than that of  
the positive controls . 
(2) Negative result:  Nonmotile organisms either do not move or move with 
Brownian motion. 
   b. Motility test 
         (1) Positive result:  Motile organisms will form a diffuse growth zone around the  
inoculum stab. 
         (2) Negative result:  Nonmotile organisms, such as B. anthracis, will form a single  
line of growth that does not deviate from the original inoculum stab. 
 
5. Quality control 
a. Positive control strain:  Pseudomonas aeruoginosa ATCC 35032 or laboratory- 
validated equivalent will demonstrate motility. 
b. Negative control strain:  Acinetobacter spp. ATCC 49139 or laboratory-validated 
equivalent will show no motility 
c. Method controls:  Perform the test with fresh cultures of the control strains  
using the same method as with unknowns.  Control strains should be assayed on 
each day of testing. 
 
6. Resolving out-of-control results 
a. Check media, reagents, controls and equipment; replace or correct as appropriate.  
Document corrective actions and repeat test. 
b. Check purity and identity of control strains and repeat testing. 
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I. Interpretation and reporting 
      
1. Presumptive identification criteria: Refer to Table A1. 
a. Direct smears from clinical samples, such as blood, CSF, or skin lesion (eschar)  
material:  Encapsulated gram-positive rods 
       b. From growth on SBA or equivalent media:  Large gram-positive rods (may stain 
gram-variable after 72 h of culture). Spores may be found in culture, under non-CO2 
atmosphere (but not on direct examination). Spores do not swell the cell and are oval-
shaped.  
    c. Rapid, aerobic growth, and tenacious colonies on sheep blood agar.  
       d. Catalase positive        
       e. Nonmotile:  In addition to B. anthracis, B. cereus var. mycoides is nonmotile. 
       f. Nonhemolytic on SBA, ground-glass appearance of colonies 
   
 2. Rule out: While hemolysis, gram stain morphology, or motility can be used for rule 
   out when the result provides clear evidence that the isolate is not B. anthracis (e.g., a  
   clearly visible zone of beta hemolysis), a combination of two Level A tests is  
   recommended for rule out. 
 
3. Reporting/action 
a. Consult with state public health laboratory director (or designate) if B. anthracis is 
suspected. 
    b. General instruction and information 
   (1) Preserve original specimens pursuant to a potential criminal investigation and  
      possible transfer to an appropriate LRN laboratory. 
(2) Environmental/nonclinical samples and samples from announced events are  
not processed by Level A Laboratory; submitter should contact the state 
public health laboratory directly. 
(3) The state public health laboratory/state public health department will coordinate 
notification of local FBI agents as appropriate. 
(4) Assist local law enforcement efforts in conjunction with guidance received from 
the state public health laboratory. 
(5) The state public health laboratory/state public health department may request 
transfer of suspicious specimens prior to presumptive testing. 
(g)  FBI and state public health laboratory/state public health department will  
      coordinate the transfer of isolates/specimens to a higher-level LRN laboratory  
as appropriate; refer to Shipping Procedure.  
c. Immediately notify state public health laboratory director (or designate) and state 
public health department epidemiologist/health officer if B. anthracis cannot be ruled 
out and a bioterrorist event is suspected. 
d. Immediately notify physician/infection control according to internal policies if B. 
anthracis cannot be ruled. 
e. If B. anthracis is ruled out, proceed with efforts to identify using established  
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Figure A6.  B. anthracis and B. cereus colony morphology; overnight cultures of B. cereus  
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IV.  Appendices  
   
A:  Appendix A: India ink stain  
 
1. Purpose:  This optional test is used to improve visualization of encapsulated B.  
anthracis in clinical samples such as blood, blood culture bottles, or cerebrospinal fluid 
(CSF).  This is not an ASM recommended procedure; performance of the test requires 
staff that are trained/ experienced with this procedure.  
 
2. Quality control 
a. Positive control strain:  Klebsiella pneumoniae (or laboratory validated equivalent) 
will demonstrate a well-defined clear zone on SBA.  
b. Negative control strain:  E. coli ATCC 25922 (or laboratory validated equivalent)  
will demonstrate no clear zone. 
c. Method controls:  Perform the test with suspensions of fresh cultures of the  
control strains.  Control strains should be assayed on each day of testing. 
d. Resolving out-of-control results:  Check media, reagents, controls and equipment;  
     replace or correct as appropriate.  Document corrective actions and repeat test.  
 
3. Procedure 
a. For the controls, transfer a small amount of growth (1 mm diameter) from each  
control SBA plate (positive control = Klebsiella pneumoniae; negative control =  
Escherichia coli ATCC 25922) into 0.5 ml saline and mix.  
b. For the unknowns, take 100 µl of sample (blood, CSF).  Transfer 5-10 µl of  
unknown  sample or control to a slide.  Place a coverslip on the drop, and then add  
5-10 µl of India ink to the edge of the coverslip.  After the ink diffuses across the  
slide, view the cells using 100X oil immersion objective with oil on top of the  
coverslip.  
    
4. Interpretation 
  a. Positive result:  The capsule will appear as a well-defined clear zone around the  
cells. 
b. Negative result:  No zone will be present.  
 
     5. Reporting/actions 
a. Clinical specimens with encapsulated (visualized with India Ink), gram-positive rods 
provide a presumptive identification of B. anthracis; it does not confirm B.  
anthracis. 
b. Every effort should be made to obtain an isolate for continued testing and referral to  
state public health laboratory. 
 
     6. Limitations 
       a. Interpretation of results requires trained/experienced staff. 
b. A negative test result should not be used to rule out B. anthracis. 
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   B. Appendix B: Nasal specimens for screening Bacillus anthracis  
 
  1. General: Nasal specimens (nares culture) should ONLY be used to support a  
confirmed exposure to B. anthracis or during an ongoing epidemiologic investigation.   
Gram stain of nasal specimens for B. anthracis spores are not recommended.  Refer to 
limitations section below. 
 
  2. Materials: Swab (Dacron, rayon or other synthetic swabs are preferred over cotton)  
    and transport medium for culture. 
 
  3. Procedure  
  a. Selection 
  (1) The specimen of choice is a swab specimen taken at least 1 cm inside the 
     nares. 
  (2) Lesions in the nose require samples from the advancing margin of the lesions. 
  b. Method 
  (1) Carefully insert the moistened swab (saline, sterile water) at least 1 cm into the 
     nares. 
  (2) Firmly sample the inside of the nares by rotating the swab and leaving it in 
     place for 10 to 15 sec. 
  (3) Withdraw the swab, insert it into its transport container, and submit the 
     sampling unit to the laboratory for culture. 
  c. Labeling 
  (1) Label the swab container with patient information. 
  (2) Indicate, if possible, the degree or likelihood of exposure. 
  d. Transport 
  (1) Transport the specimen to the laboratory as soon as possible. 
  (2) Do not refrigerate specimens for culture.  
e. Culture: Heat Shock 
         (1)  Remove the swab from transport container and place it into 1.5 ml of sterile  
            saline or a nutrient broth such as trypticase soy broth, brain heart infusion  
            broth, or equivalent.  Vigorously twist the swab, and recap the tube. 
         (2) Leave the swab in the tube.  Place the broth suspension into a 65oC water bath  
            for 30 min.  
        (3) Plate 100-200 µl of broth on 5% sheep blood agar plate and incubate at  
           35-37oC for 18-24 h.  Many B. anthracis will have visible growth in 12-18 h. 
           Observe for characteristics of B. anthracis. 
 
  4. Interpretation:  Observe colony morphology for typical Bacillus colonies, look for 
    lack of hemolysis, perform Gram stain, and evaluate for B. anthracis characteristics 
    as described in the Level A laboratory protocol. 
 
  5. Reporting:  If B. anthracis cannot be ruled out, submit the isolate to the state public  
    health laboratory/department for confirmation.  Refer to Level A reporting section.  
   
   6. Limitations: Nasal cultures taken to evaluate for the presence of anthrax spore 
    have not been evaluated for sensitivity or specificity.  Nasopharyngeal and throat  
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    specimens are not recommended for anthrax screens and should not be submitted.  
    Nasal cultures are NOT recommended for screening those who are asymptomatic and 
without known exposure. 
     
7. Procedure Notes 
a. Anterior nares cultures, without an indication of the presence of a lesion, are 
  routinely examined only for presence of Staphylococcus aureus and β-hemolytic  
    streptococci.  Because of the unknown sensitivity of this method for detecting B. 
    anthracis spores, interpret negative results with caution. 
  b. Anterior nares cultures cannot be used to predict a subsequent infection with B.  
anthracis, and should not be submitted in lieu of blood and other appropriate 
specimens  from symptomatic patients. 
   c.  Anaerobic cultures are not done on nasal specimens.  B. anthracis produces spores in 
culture only when grown in air. 
   d. Nasal swabs may also be plated directly onto sheep blood agar prior to or without heat 
shocking, however normal nasal flora may overgrow very low numbers of Bacillus 
colonies.   
  e. Pediatric needs:  Use the same procedure substituting a small fine-wire or 
    nasopharyngeal swab to sample the anterior nares. 
 
 C. Appendix C: Change record 
 
   1.  18 Mar. 2002 (ban.asm.cp.la.021402) 
     a. Recommend use of TSB, or equivalent, for wet mount procedure (II. H. 2. a.) 
     b. Added criteria for rule out at Level A (II. I. 2.) 
    
   2. 06 Nov. 2001 (ban.asm.cp.la.110501) 
     a.  Figure A1 and text (II. F. 2. c.) revised to state “frequently” occur as long chains of  
       bacilli. 
     b.  File name, date, page information added to footer. 
     c. Change record added to appendices 
    
   3. 29 Oct. 2001 (ban.asm.cp.la.102901f) 
     a. Nasal swab procedure added. 
      b. File name, date, page information deleted from footer (an error). 
    
   4. 24 Oct. 2001 (ban.asm.cp.la.102401f):  Original ASM/APHL/CDC Level A procedure  
     for B. anthracis loaded to ASM public site. 
      
 
